Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) has earned a consensus recommendation of "Hold" from the fourteen brokerages that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $45.83.
A number of equities research analysts recently weighed in on the company. DZ Bank downgraded Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a research report on Friday, July 29th. JPMorgan Chase & Co. dropped their price objective on Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report on Monday, August 1st. UBS Group downgraded Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a research report on Friday, July 29th. Berenberg Bank dropped their price objective on Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a research report on Wednesday, August 10th. Finally, Truist Financial lowered their price target on Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a "hold" rating for the company in a report on Wednesday, June 22nd.
Get Fresenius Medical Care AG & Co. KGaA alerts:Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. SRS Capital Advisors Inc. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 36.0% in the first quarter. SRS Capital Advisors Inc. now owns 1,545 shares of the company's stock worth $52,000 after purchasing an additional 409 shares during the last quarter. Signaturefd LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 26.4% in the first quarter. Signaturefd LLC now owns 2,190 shares of the company's stock worth $74,000 after purchasing an additional 458 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 1.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 53,824 shares of the company's stock worth $1,747,000 after purchasing an additional 516 shares during the last quarter. Timber Creek Capital Management LLC raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 0.3% in the second quarter. Timber Creek Capital Management LLC now owns 199,285 shares of the company's stock worth $4,970,000 after purchasing an additional 542 shares during the last quarter. Finally, Wetherby Asset Management Inc. raised its stake in shares of Fresenius Medical Care AG & Co. KGaA by 9.0% in the first quarter. Wetherby Asset Management Inc. now owns 6,807 shares of the company's stock worth $229,000 after purchasing an additional 560 shares during the last quarter. 5.59% of the stock is currently owned by hedge funds and other institutional investors.
Fresenius Medical Care AG & Co. KGaA Price Performance
FMS opened at $16.67 on Monday. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $16.06 and a 12-month high of $36.84. The business's fifty day simple moving average is $19.14 and its 200-day simple moving average is $26.28. The company has a market capitalization of $9.77 billion, a price-to-earnings ratio of 10.62, a PEG ratio of 0.84 and a beta of 1.03. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47.About Fresenius Medical Care AG & Co. KGaA
(Get Rating)
Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Stories
- Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
- Kroger's is Your One-Stop Consumer Staples Stock
- Adobe Perfects the Art of the Faceplant for Investors
- Tax Credits are the Incentives in the Inflation Reduction Act
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.